Eyonis Inc. to Showcase AI in Lung Cancer Detection at CHEST 2026

eyonis Inc., a subsidiary of Median Technologies, will present study results on the performance of the eyonis® Lung Cancer Screening (LCS) software at the CHEST 2026 Annual Meeting in Phoenix. The study highlights a 93.3% sensitivity, 92.4% specificity, and a 99.9% negative predictive value for eyonis® LCS, which is FDA-cleared as the first AI/ML-based software for lung cancer screening.

The event provides a platform to engage with pulmonologists, crucial for adopting AI-driven solutions in clinical practice. The detailed presentation by Benoit Huet, PhD, will feature on October 19. The software's capabilities, including nodule detection and malignancy assessment, aim to enhance decision-making in healthcare facilities.

Following its FDA clearance in February 2026, the company seeks to expand its commercial deployment in the U.S., engaging with key stakeholders like pulmonologists and screening centers to integrate eyonis® LCS into cancer screening workflows.